I-Taxotere ye-Cancer Prostate - Ngabe Isebenza Nini?
I-Taxotere (i-docetaxel) isebenza nini futhi nini yokwelapha umdlavuza wesifo sofuba ?
Iyakhokhisa kanjani (i-Docetaxel) isebenza?
I-taxotere (docetaxel) isebenza ngokufanayo nemithi eminingi ye-chemotherapy ngokuphazamisa ukuhlukaniswa kweseli (okuthiwa i-mitosis). Njengoba amangqamuzana omdlavuza amanye amangqamuzana ehlukanisa ngokushesha kakhulu emzimbeni, lawa maseli abhekene nezithandane ezenzelwe i-Taxotere futhi, ngenxa yalokho, afe ngamanani aphakeme lapho umuthi uphathwa.
Ngaphezu komdlavuza wesicathulo, i-Taxotere ingasetshenziselwa abantu abanezinhlobo ezithile zomdlavuza wamaphaphu, umdlavuza webele, noma umdlavuza we-ovarian.
Umlando - I-Taxotere ye-Hormone-Resistant Advanced Prostate Cancer
I-Taxotere yalethwa emithonjeni enkulu yokwelapha umdlavuza we-prostate ngemva kokutadisha ku- New England Journal of Medicine ngo-2004 okwakubonisa ukuthi i-Taxotere ehlangene ne-steroid prednisone yabangela ukusinda okuthuthukisiwe uma kuqhathaniswa nesidakamizwa esisezingeni elifanayo somdlavuza we-prostate ophakeme , mitoxantrone. I- New England Journal iphinde ikhombise ukuthi labo madoda abaphathwa nge-Taxotere babe nekhwalithi ephelele yokuphila kanye nokulawulwa kobuhlungu obuthuthukisiwe. Ngaleso sikhathi, i-Taxotere yayibhekwa njengokwelashwa okukhethwe umdlavuza we-prostate ophezulu emadodeni ayenomdlavuza wesifo sofuba owasakaze ngaphesheya kwe-prostate futhi waba umelana ne- hormone therapy .
I-Taxotere isabhekwa njengento enhle (kanye neminye imithi efundiswayo) ukuze isetshenziswe emadodeni anomdlavuza we-metastatic prostate oye waba umelana ne-hormone therapy (ukwelashwa kwe-androgen.)
I-Now-Taxotere ye-Early Hormone-Ephuthele I-Metastatic Cancer Prostate
Izifundo ezinkulu ezifana nesilingo se-CHAARTED phakathi kwabanye ziye zashintsha indlela yokudla komdlavuza we-hormone-sensitive sensitive prostate for amadoda amaningi. Lezi zomshukela zingase zibe nemetastatic ngesikhathi sokuxilongwa noma ziye zaba nemastatic emva kokuqala ukwelapha umdlavuza wendawo prostate .
Nakuba ukwelashwa kwe-Taxotere ngaphambilini kwasetshenziselwa amadoda aphethe umdlavuza we-prostate ophakeme owaye waba umelana nokuthelela kwe-hormone, kubonakala sengathi ukusebenzisa ukwelashwa kwe-Taxotere kusenesikhathi - ngesikhathi esifanayo lapho ukwelashwa nge-hormonal therapy kuqala - kunenzuzo kokubili ukuqhubeka-mahhala ukusinda nokuphila jikelele. Ngokuqinisekile, i-Taxotere inemiphumela emibi yokukhathazeka njenganoma imuphi umuthi we-chemotherapy, kodwa lokhu, kanye nentuthuko ngokusebenzisa ezinye imithi, kuyisibonakaliso esithakazelisayo senqubekela phambili ekwelapheni umdlavuza wesibeletho.
I-Taxotere ye-Cancer Advanced Prostate Cancer
I-STAMPEDE Trial yaqasha amadoda anomdlavuza we-prostate osendaweni yangakini. Amadoda awanikezwa i-Taxotere ngaleso sikhathi ukwelashwa kwe-hormone aqalisiwe atholakale enesifo esingcono kakhulu sokungenwa kwezifo kanye nalabo ababenakekelwa nge-hormonal therapy kuphela. I-caveat yilapho amadoda angcono kakhulu okukhethwa kulolukwelapha yilabo abanomdlavuza we-prostate ophezulu.
I-Adjuvant Treatment ye-High-Risk Localized Cancer Cancer Localized
Kwabesilisa abanesicathulo se-prostate esendaweni yangakini abanengozini enkulu, besebenzisa i-Taxotere esimweni sokukhangisa (uma kwenzeka "isimo") sitholwa ngokunciphisa kakhulu izigameko zokusabalalisa okude (umthamo) we-cancer yabo yesicathulo.
Laba bantu baphathwa nge-Taxotere kanye nokwelashwa kwama-hormonal kanye nokwelashwa kwama- radiation , kunokuthi ukwelashwa kwe-hormonal kanye nokwelapha kwama-radiation kuphela. Yiqiniso, i-Taxotere inemiphumela emibi engalungile okumele icatshangelwe.
Yiziphi Imiphumela Ezingezansi
Njengazo zonke izidakamizwa ze-chemotherapy, kunezimo ezimbi ezihlukahlukene ezingenzeka uma uthatha i-Taxotere. Ungazijwayele ezinye zazo njengoba zijwayele izinhlobo eziningi ze-chemotherapy. Imiphumela emibi elandelayo yenzeka ngaphezu kwengxenye yesithathu yabantu abasebenzisa i-Taxotere:
- I-Neutropenia - Inani eliphansi elimhlophe legazi elingase lifake isandulela ngculaza.
- I-anemia - Inani elincane elibomvu lamasosha egazi elingabangela ukhathala phakathi kwezinye izimpawu.
- Ukulahlekelwa izinwele
- Ukugcinwa kwe-Fluid
- Uhudo
- I-nausea - Lesi sibonakaliso sivame ukulawulwa kahle kakhulu ngemithi ekhona manje yokulwa nesicanshu
- Ukushona
- Izilonda zomlomo
- Izinguquko ze-fingernail
- Ukusabela okweqile - Lokhu kuvamile, futhi imishanguzo yokulwa nezimpawu zokugula zivame ukunikezwa kanye nokukhipha.
Imithombo:
Fizazi, K., Jenkins, C., no-I. Tannock. Ingabe i-docetaxel kufanele ibe yinkinga yokunakekela iziguli ezine-metastatic-sensitive sensitive prostate cancer? I-pro neyokuphikisana. Amanothi we-Oncology . 2015. 26 (8): 160-7.
I-Goodman, i-A. Docetaxel Ehlangene Ne-Hormone Therapy Yandisa Ukusinda Emdlalweni Ophezulu We-Cancer. I-ASCO Post . http://www.ascopost.com/issues/may-25,-2015/docetaxel-combined-with-hormone-therapy-extends-survival-in-advanced-prostate-cancer.aspx.
UJames, uN., uSydes, M., Clarke, N. et al. Ukwengezwa kwe-docetaxel, i-zoledronic acid, noma kokubili ukuya kokwelashwa kwe-hormone yesikhathi eside emdlalweni wesibeletho se-prostate (STAMPEDE): imiphumela yokusinda kusuka ku-trial adapter, multiarm, multistage, yesikhulumi esilawulwa ngokungahleliwe. I-Lancet . 2015 Dec 21. (Epub ngaphambi kokuphrinta).
UMartel CL, uGumerlock PH, Meyers FJ, et al. Amasu amanje ekulawulweni komdlavuza we-hormone refractory prostate. I-Cancer Yiphathe uMsindisi 2003; 29: 171-187.
I-National Cancer Institute. Ucwaningo lwezimali lwe-NIH lubonisa ukusinda okuqhubekayo emadodeni anomdlavuza we-metastatic prostate othola i-chemotherapy lapho eqala ukwelashwa kwe-hormone. http://www.cancer.gov/news-events/press-releases/2013/E3805.
Tannock IF, de Wit R, Berry WR, et al. I-Docetaxel kanye ne-prednisone noma i-mitoxantrone kanye ne-prednisone yomdlavuza ophezulu we-prostate. N. Engl. J. Med. 351 (15): 1502-12.